Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Denali Therapeutics (DNLI) Short term Debt (2022)

Historic Short term Debt for Denali Therapeutics (DNLI) over the last 1 years, with Q4 2022 value amounting to $4.4 million.

  • Denali Therapeutics' Short term Debt changed N/A to $4.4 million in Q4 2022 from the same period last year, while for Dec 2022 it was $4.4 million, marking a year-over-year change of. This contributed to the annual value of $4.4 million for FY2022, which is N/A changed from last year.
  • As of Q4 2022, Denali Therapeutics' Short term Debt stood at $4.4 million.
  • Over the past 5 years, Denali Therapeutics' Short term Debt peaked at $4.4 million during Q4 2022, and registered a low of $1.4 million during Q3 2022.